Introduction
============

Acute kidney injury (AKI) is increasingly prevalent worldwide and is associated with higher morbidity and mortality.^[@b1]^ Recent studies in the developed world report AKI in 3.2% to 9.6% of admissions, resulting in in‐hospital mortality rates ranging from 20% to 50%.^[@b2]^ The incidence of AKI requiring dialysis is increasing at the rate of 10% per year in the United States and is higher than that of end‐stage renal disease (ESRD).^[@b3]^ Even though the recovery of kidney function following AKI is an important determinant of morbidity and has long‐term implications for the health and well‐being of patients, there is a lack of investigations on this topic.^[@b4]^

Cardiovascular disease is the main cause of death for patients on dialysis, and stroke is the third leading cause of cardiovascular disease--related death and disability.^[@b5]^ Rapidly declining renal function may augment the risk of cardiovascular events independently from baseline renal function.^[@b6]^ There are several potential pathophysiological mechanisms by which AKI may directly contribute to an increased risk of cardiovascular disease independent of the impact on chronic kidney disease (CKD) progression.^[@b7]^ AKI can lead to an increase in microvascular permeability in the brain, and acute uremia may induce proinflammatory chemokines that are mechanistically responsible for a leaky blood--brain barrier.^[@b8]^ Although both AKI and stroke may result from atheroembolic events and are independent predictors of mortality, it has been suggested that the 2 entities may interact in the pathophysiology.^[@b9]--[@b10]^ Few studies, however, have explored the impact of the development and severity of AKI on progression to de novo stroke.

We hypothesized that dialysis‐requiring AKI, even for only a temporary period, would have an adverse effect on first‐ever incident stroke among hospitalized patients. We used data from Taiwan\'s National Health Research Institute (NHRI) to examine whether recovery from AKI after dialysis is a risk factor for long‐term stroke and compared the impact on stroke with other known atherosclerotic risk factors such as diabetes mellitus (DM).^[@b11]^

Patients and Methods
====================

Data Sources
------------

The Taiwan National Health Insurance (NHI) program is a nationwide insurance program that covers outpatient visits, hospital admissions, prescriptions, intervention procedures, and disease profiles for \>99% of the population of Taiwan (23.12 million people in 2009).^[@b12]^

The NHRI uses the original data of the NHI program to construct a longitudinal database of patients admitted between 1999 and 2008. This cohort includes 2 619 534 hospitalized patients, representing 10% of all NHI enrollees. This sampling fraction (a 3.4:1 ratio) is based on a regulation that limits the maximal amount of NHI data that can be extracted for research purposes. The NHRI database is one of the largest and most comprehensive databases in the world and has been used extensively in various studies on prescription use, diagnoses, and hospitalizations.^[@b13]--[@b15]^

Research Variables
------------------

The demographic and clinical characteristics of the participants at the index hospitalization were recorded. The parameters included age, sex, year of admission, hospital characteristics, prevalence of selected comorbid conditions, Charlson comorbidity index,^[@b16]^ organ dysfunction developing during the index hospitalization, the categories of major operations, intensive care unit admission, and outcomes. CKD codes were further validated, and the results showed a highly positive predictive value The anticoagulation prescriptions customarily used for ischemic stroke, including clopidogrel (B01AC04), acetylsalicylic acid (B01AA0), and vitamin K antagonists (B01AA0), were also identified. To determine preexisting comorbidities, we used a relatively strict criterion---at least 1 inpatient admission or 3 outpatient visits to treat a certain disease during the year prior to the index hospitalization---that was well validated with good predictive power.^[@b17]--[@b18]^ Septicemia was defined based on the International Classification of Diseases, 9th revision, clinical modification (ICD‐9‐CM) codes 003.1, 036.2, and 038.^[@b19]^ The identification of patients with severe sepsis was similar to that used by Angus et al^[@b20]^ and in our previous report^[@b21]^ and included all acute‐care hospitalizations with ICD‐9‐CM codes for bacterial or fungal infections and a diagnosis of acute organ dysfunction. Sepsis was defined according to the American College of Chest Physicians/Society of Critical Care Medicine guidelines as systemic inflammatory syndrome in response to an infection that, when associated with acute organ dysfunction, is said to be severe.^[@b22]^ Cigarette smoking is also likely to influence stroke; however, information on smoking is not available in the NHRI database. According to the surgeon general\'s reports,^[@b23]^ chronic obstructive pulmonary disease, coronary artery disease, DM, and lung cancer are highly related to smoking and could be used as proxies for cigarette smoking. Consequently, we used joint modeling of multiple diseases to capture the effect of smoking on the risk of stroke.^[@b24]^

Identification of Cases and Controls
------------------------------------

The study group consisted of those aged ≥18 years with a first diagnosis of dialysis‐requiring AKI, according to procedural codes. The dialysis certificate data in Taiwan are highly reliable because they are used for insurance payments.^[@b25]^

We used a 1‐year period prior to the index hospitalization to identify preadmission comorbidities, AKI, and dialysis. Patients with preadmission AKI, ESRD, or stroke and those who had undergone kidney transplantation were excluded. Patients who underwent placement of a vascular access or peritoneal‐dialysis catheter were also excluded. [Figure 1](#fig01){ref-type="fig"} shows the patient‐selection flow chart. Only those who survived for \>30 days after discharge from the index hospitalization and who were not readmitted to hospital and did not receive further dialysis were enrolled as the AKI‐recovery group. A control cohort without AKI, dialysis, or incident stroke before and during the index hospitalization and matched for age, sex, the same calendar year of index hospitalization, and propensity score adjusted for acute dialysis during hospitalization with the study group (AKI‐recovery group) was selected for comparison (non‐AKI group). The patients were further divided into 4 mutually exclusive subgroups for further analysis: non‐DM/non‐AKI, AKI alone, DM alone, and AKI with DM.

![Flow diagram of the enrollees. AKI indicates acute kidney injury; ESRD, end stage renal disease.](jah3-3-e000933-g1){#fig01}

Definition of De Novo Stroke
----------------------------

De novo stroke was defined as one of the following conditions in those who had no history of stroke at baseline:^[@b26]^ (1) records of emergency‐room service or hospitalization claim for \>1 day or records of emergency‐room service with ICD‐9‐CM codes of 430 to 438 followed by claims for various brain‐imaging studies (computed tomography, magnetic resonance imaging, transcranial or carotid Doppler sonography) or claims for rehabilitation and anticoagulation prescriptions customarily used for ischemic stroke; (2) records of \>3 consecutive outpatient visits with the codes and claims for examinations, services, or prescriptions as described for condition 1. In Taiwan, all medical facilities capable of admitting stroke patients are equipped with computed tomography or magnetic resonance imaging scanners, which considerably increase the validity of stroke diagnosis.^[@b27]^ Severe stroke was defined as those who were admitted to an intensive care unit within 30 days after the stroke event. A reproducibility study in Taiwan reported that the ICD‐9‐CM code for stroke from the hospital discharge data in the NHRI database was highly accurate.^[@b17]--[@b18],[@b28]--[@b29]^ Each patient was followed from the date of discharge to the first documented date of de novo stroke, death, or the end of the study (December 31, 2007), whichever occurred first. The patients were enrolled from 1998 to 2006; therefore, there was a 1‐year latency period to ascertain that the patients were free of stroke after AKI.

The National Taiwan University Study Group on Acute Renal Failure (NSARF) 2002--2010
------------------------------------------------------------------------------------

The NSARF,^[@b30]--[@b34]^ a multicenter prospective database, was used to validate baseline kidney function and the inclusion criteria for each risk group in this study to assess subsequent stroke events. CKD was defined according to an estimated glomerular filtration rate ≤45 mL/min per 1.73 m^2^,^[@b34]^ and AKI was defined according to the RIFLE (risk, injury, failure, loss, and end stage) criteria.^[@b35]^ We included NSARF 2002--2010 participants who were followed up to September 2012 with complete data on serum creatinine (measured following a standardized protocol).

Statistics
----------

Continuous variables are described as mean±SD, and discrete variables are presented as counts or percentages. All data were analyzed using R software, version 2.8.1 (Free Software Foundation Inc, Boston, MA). A 2‐sided *P*\<0.05 was considered to be statistically significant.

We calculated propensity score in an attempt to make an unbiased estimate of all the confounders predicting dialysis to balance the study and control groups during the index hospitalization, as a binary dependent variable, under a set of covariates. The predicted probability derived from the logistic equation was used as the propensity score for each individual.

To make comparisons comparable, each subject in the AKI‐recovery group was matched 1:1 with a subject in the control group. We calculated the Mahalanobis distances using of all the chosen important variables to find the nearest available subject within the specified propensity score caliper from the control group.

Due to the strong correlation among CKD, ESRD,^[@b36]--[@b37]^ anticoagulation agents, and incident stroke or mortality, we used a Cox proportional hazards model with time‐varying covariates to evaluate the impact of subsequent ESRD, CKD, and anticoagulation treatment after discharge on the risk of stroke events or mortality. This model assumed that changes in CKD or ESRD status or medications could appear at a subsequent time point after discharge. The medications used 14 days before incident stroke were identified. The Kaplan--Meier method was used to estimate survival curves, and the log‐rank test was used to test homogeneity between survival curves. For the outcome measurements, an individual was censored at death or at the end of the measured period.

Ethical Considerations
----------------------

Informed consent was originally obtained by the NHRI, and because the patients were not identifiable in the present study, informed consent was not required. In addition, because the identification numbers of all individuals in the NHRI databases are encrypted to protect privacy, this study was exempt from full ethical review by the National Taiwan University Hospital Review Board.

Results
=======

Demographic Characteristics of the Patients
-------------------------------------------

Of 42 862 adult patients with AKI and dialysis from 1999 to 2008 who were screened, 3861 died during the index hospitalization, and 6633 died within 30 days after discharge (most were discharged with "do not resuscitate" orders). In total, 12 170 patients survived to 30 days after hospital discharge. Among them, 4502 patients withdrew from dialysis due to renal function recovery, and the rest (7568 patients) did not. During the matching procedure, 187 patients were excluded because no matching subjects were found. Consequently, 4315 patients were enrolled into the AKI‐recovery group, and 4315 patients were enrolled into the non‐AKI group (without AKI or dialysis or prior stroke) (men, 57.7%; mean age, 62.8±16.8 years in both groups; [Figure 1](#fig01){ref-type="fig"}, Tables [1](#tbl01){ref-type="table"} and [2](#tbl02){ref-type="table"}).

###### 

Demographics and Comorbidities Added Into a Nonparsimonious Propensity Model to Predict Dialysis at Index Hospitalization[\*](#tf1-1){ref-type="table-fn"}

                                               OR      Lower 95% CI   Upper 95% CI   *P* Value
  -------------------------------------------- ------- -------------- -------------- -----------
  Male                                         1.11    1.04           1.18           \<0.001
  Age (per year)                               1.02    1.02           1.02           \<0.001
  Premorbid risk                                                                     
  Charlson score                               1.25    1.21           1.29           \<0.001
  Congestive heart failure                     1.87    1.67           2.08           \<0.001
  Dementia                                     0.67    0.54           0.82           \<0.001
  COPD                                         0.55    0.50           0.61           \<0.001
  Rheumatologic disease                        2.23    1.73           2.83           \<0.001
  Hemiplegia                                   0.69    0.52           0.91           0.009
  Tumor                                        0.82    0.69           0.98           0.030
  Diabetes mellitus                            2.28    2.10           2.48           \<0.001
  Moderate or severe liver disease             2.64    2.10           3.28           \<0.001
  Chronic kidney disease                       5.37    4.72           6.11           \<0.001
  Index hospital comobidity                                                          
  Respiratory                                  2.69    2.46           2.94           \<0.001
  Neurologic                                   2.41    1.89           3.04           \<0.001
  Hematologic                                  2.99    2.30           3.84           \<0.001
  Metabolic                                    14.08   11.27          17.51          \<0.001
  Operative categories                                                               
  Cardiothoracic                               1.23    1.02           1.48           0.027
  Upper GI                                     0.49    0.35           0.67           \<0.001
  Hepatobiliary                                0.56    0.43           0.72           \<0.001
  ICU admission during index hospitalization   19.79   18.48          21.20          \<0.001

The propensity score in an attempt to make an unbiased estimated of all the confounders to balance study and control groups and further add to the Cox regression model. AKI indicates acute kidney injury; COPD, chronic obstructive pulmonary disease; ESRD, end‐stage renal disease; GI, gastrointestinal; ICU, intensive care unit.

The propensity model for predicting the need for dialysis during index hospitalization in both groups had a high discrimination power (estimated area under the receiver operating characteristic curve: 0.937), and it fit well with the observed binary data (adjusted generalized *R*^2^=0.35).

###### 

Characteristics of the Patients in the Study Groups

                                                                            AKI‐Recovery Group (n=4315)   Non‐AKI Group (n=4315)   *P* Value
  ------------------------------------------------------------------------- ----------------------------- ------------------------ -----------
  Male                                                                      2488 (57.7%)                  2488 (57.7%)             0.999
  Age (per year)                                                            62.8±16.8                     62.8±16.8                0.946
  Premorbid risk                                                                                                                   
  Charlson score                                                            1.9±1.9                       1.9±2.03                 0.242
  Myocardial infarction                                                     163 (3.8%)                    161 (3.7%)               0.955
  Congestive heart failure                                                  534 (12.4%)                   477 (11.1%)              0.061
  Atrial fibrillation                                                       129 (3%)                      128 (3%)                 0.999
  Peripheral vascular disease                                               69 (1.6%)                     81 (1.9%)                0.365
  Dementia                                                                  82 (1.9%)                     80 (1.9%)                0.937
  COPD                                                                      474 (11%)                     448 (10.4%)              0.384
  Lung cancer                                                               15 (0.3%)                     31 (0.7%)                0.026
  Diabetes mellitus                                                         720 (16.7%)                   713 (16.5%)              0.862
  Coronary artery disease                                                   655 (15.2%)                   650 (15.1%)              0.904
  Rheumatologic disease                                                     65 (1.5%)                     70 (1.6%)                0.729
  Peptic ulcer                                                              562 (13%)                     561 (13%)                0.999
  Hemiplegia                                                                17 (0.4%)                     14 (0.3%)                0.720
  Tumor                                                                     323 (7.5%)                    344 (8%)                 0.420
  Moderate or severe liver disease                                          322 (7.5%)                    310 (7.2%)               0.649
  Chronic kidney disease                                                    521 (12.1%)                   508 (11.8%)              0.690
  Hypertension                                                              1806 (41.9%)                  1806 (41.9%)             0.999
  Dyslipidemia                                                              406 (9.4%)                    415 (9.6%)               0.769
  Index hospital comorbidity                                                                                                       
  Cardiovascular                                                            320 (7.4%)                    320 (7.4%)               0.999
  Respiratory                                                               768 (17.8%)                   731 (16.9%)              0.306
  Hepatic                                                                   95 (2.2%)                     101 (2.3%)               0.718
  Neurologic                                                                79 (1.8%)                     93 (2.2%)                0.317
  Hematologic                                                               67 (1.6%)                     82 (1.9%)                0.247
  Metabolic                                                                 116 (2.7%)                    77 (1.8%)                0.006
  Septicemia                                                                162 (3.8%)                    116 (2.7%)               0.006
  Severe sepsis                                                             99 (2.3%)                     94 (2.2%)                0.771
  Operative categories                                                                                                             
  Cardiothoracic                                                            177 (4.1%)                    187 (4.3%)               0.630
  Upper GI                                                                  30 (0.7%)                     32 (0.7%)                0.899
  Lower GI                                                                  96 (2.2%)                     102 (2.4%)               0.719
  Hepatobiliary                                                             60 (1.4%)                     51 (1.2%)                0.445
  ICU admission during index hospitalization                                2777 (64.4%)                  2817 (65.3%)             0.379
  After discharge concomitant medication[\*](#tf2-1){ref-type="table-fn"}                                                          
  Acetylsalicylic acid                                                      832 (19.3%)                   972 (22.5%)              \<0.001
  Clopidogrel                                                               496 (11.5%)                   510 (11.8%)              0.663
  Vitamin K antagonists                                                     352 (8.2%)                    178 (4.1%)               \<0.001
  Outcomes                                                                                                                         
  Mortality                                                                 2353 (54.5%)                  1306 (30.3%)             \<0.001
  ESRD                                                                      861 (20%)                     73 (1.7%)                \<0.001
  Stroke events                                                             219 (5.1%)                    172 (4%)                 0.017
  Stroke with ventilator                                                    28 (0.6%)                     7 (0.2%)                 \<0.001
  Severe stroke[\*](#tf2-2){ref-type="table-fn"}                            41 (1.0%)                     18 (0.4%)                0.004

Number as percentage and, mean ± SD. AKI indicates acute kidney injury; COPD, chronic obstructive pulmonary disease; ESRD, end stage renal disease; GI, gastrointestinal; ICU, intensive care unit.

The medications used during 14 days before the incident stroke.

Severe stroke was defined as being admitted to an ICU within 30 days after the stroke event.

The mean Charlson score before the index admission was 1.9±1.9. The premorbid risks were not statistically different between the 2 groups; however, the non‐AKI group had a higher rate of metabolic comorbidities during the index hospitalization (*P*=0.006: [Table 2](#tbl02){ref-type="table"}). Most of the patients with hemiplegia had traffic accident--related cervical trauma (83%), followed by tumor‐related compression (13%).

Outcome Measurements
--------------------

### Long‐term incident stroke and all‐cause mortality

Our findings showed a higher rate of incident stroke in the AKI‐recovery group than in the non‐AKI group (*P*\<0.05). After a mean follow‐up period of 3.36 years, the unadjusted rate of incident stroke was higher in the AKI‐recovery group than in the non‐AKI group (15.6 versus 11.5 per 1000 person‐years, respectively).

More patients in the AKI‐recovery group who had a stroke had used ventilators (*P*=0.001) and been admitted to critical care units (*P*\<0.004) than the non‐AKI patients. Compared with the non‐AKI group, the AKI‐recovery group had a higher risk (*P*=0.037) of incident stroke after adjustment for other variables. The impact was independent of age (*P*\<0.001), myocardial infarction (*P*\<0.001), hemiplegia (*P*\<0.001), DM (*P*=0.001), chronic obstructive pulmonary disease (*P*=0.012), atrial fibrillation (*P*=0.034), septicemia (*P*=0.003), subsequent ESRD (*P*\<0.001), or CKD (*P*=0.00) after the index discharge. The final model had good discrimination (C‐index: 0.73) ([Table 3](#tbl03){ref-type="table"}). The proxy for cigarette smoking, lung cancer, was not independently related to de novo stroke. Kaplan--Meier curves showed that the AKI‐recovery group had a significantly higher risk of stroke compared with the non‐AKI group ([Figure 2](#fig02){ref-type="fig"}).

###### 

Factors Related to Developing Long‐term Incident Stroke[\*](#tf3-1){ref-type="table-fn"}

                            HR     Lower 95% CI   Upper 95% CI   *P* Value
  ------------------------- ------ -------------- -------------- -----------
  Age (per year)            1.03   1.01           1.05           \<0.001
  Premorbid risk                                                 
  Hemiplegia                4.67   1.92           11.33          \<0.001
  Diabetes mellitus         1.54   1.19           1.98           0.001
  Hypertension              1.49   1.20           1.86           0.004
  Atrial fibrillation       1.69   1.04           2.74           0.034
  COPD                      1.69   1.12           2.55           0.012
  Myocardial infarction     3.75   1.98           7.11           \<0.001
  AKI‐recovery vs non‐AKI   1.25   1.10           1.65           0.037
  Septicemia                2.31   1.87           2.75           0.003
  Varying‐time factors                                           
  Varying‐time ESRD         1.95   1.46           2.64           \<0.001
  Varying‐time CKD          1.60   1.16           2.21           0.004

AKI indicates acute kidney injury; CI, confidence interval, CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ESRD, end‐stage renal disease; HR, hazard ratio.

The final model had good discrimination (C‐index=0.73).

![Kaplan--Meier curves of being free from stroke in the AKI‐recovery and non‐AKI groups (*P*=0.0025, log‐rank test). AKI indicates acute kidney injury.](jah3-3-e000933-g2){#fig02}

There were 2353 deaths (54.5%) in the AKI‐recovery group and 1306 deaths (30.3%) in the non‐AKI group. The incidence of all‐cause mortality was 161.6 per 1000 person‐years in the AKI‐recovery group. The AKI‐recovery group had a higher risk of mortality than the non‐AKI group (hazard ratio: 2.38; 95% CI: 1.64 to 3.44; *P*\<0.001).

### Incident stroke stratified by diabetes and AKI status

There was no statistically significant difference in de novo stroke between the AKI‐alone group and the DM‐alone group (as reference) after adjusting for comorbidities and subsequent CKD, ESRD, and anticoagulation treatment after hospital discharge (*P*=0.086). The patients in the non‐DM/non‐AKI group had a lower risk of stroke than the DM‐alone group (hazard ratio: 0.56; 95% CI 0.38 to 0.84; *P*=0.005).

### Sensitivity analysis

When considered as separate outcomes, the hospitalization rates for both ischemic and hemorrhagic strokes were also markedly higher in the AKI‐recovery group than in the non‐AKI group (ischemic: 4.7% versus 3.7%, *P*=0.017; hemorrhagic: 0.7% versus 0.3%, *P*=0.036). Further time‐varying Cox regression analysis by ischemic stroke also confirmed that the AKI‐recovery group had a higher risk of ischemic stroke than the non‐AKI group (hazard ratio: 1.23; 95% CI: 1.01 to 2.4; *P*=0.047).

Furthermore, the increased risk of long‐term stroke events following AKI recovery was consistent across the subgroups ([Figure 3](#fig03){ref-type="fig"}). This was especially true among the patients with or without traditional cardiovascular risk factors, prior DM, hypertension, or dyslipidemia.

![Hazard ratio of stroke stratified according to prior hypertension, diabetes, or dyslipidemia. AKI indicates acute kidney injury; HR, hazard ratio.](jah3-3-e000933-g3){#fig03}

### Patients with incident stroke and subsequent long‐term mortality

Further analysis using the time‐varying Cox regression model revealed that the AKI‐recovery group had a higher long‐term mortality rate after subsequent stroke events. The results indicated that long‐term mortality was also associated with temporary dialysis (hazard ratio: 2.38; 95% CI: 1.64 to 3.44; *P*\<0.001) in patients after subsequent stroke events. This model showed good discrimination with a C‐index of 0.73.

### Unmatched group

There were 187 participants (4.15%) with AKI and dialysis who could not be matched with a suitable control. Their incidence rates of stroke events and all‐cause mortality were 23.6 and 302 per 1000 person‐years, respectively, which were higher than those of the enrollees.

### Validation

Among the NSARF 2002--2010 participants, 503 nonstroke patients in the AKI‐recovery group and 114 384 patients without acute dialysis and who survived to hospital discharge were examined as the non‐AKI group. The baseline CKD ratio was 1.4% among the non‐AKI group and 16.7% among the AKI‐recovery group.

Consistent with our previous findings, after adjusting for baseline comorbidities including CKD status, the AKI‐alone group had a similar long‐term risk of stroke events as those with DM alone (*P*=0.745) after a median follow‐up of 4.03 years (range: 1.57 to 6.21 years).

Discussion
==========

In this population‐based cohort study, we found that dialysis‐requiring AKI, even if only temporary dialysis, was associated with an increased risk of developing stroke, and its impact was similar to DM. This suggests that all patients with AKI, regardless of the presence or extent of traditional cardiovascular risk factors, should be closely monitored for subsequent stroke.

AKI is now a global health problem,^[@b38]^ and the findings of the current study are noteworthy from the perspective of a clinician caring for a patient with AKI requiring dialysis. In recent decades, increased understanding of AKI epidemiology^[@b39]^ and improvements in posthospitalization resource utilization^[@b40]--[@b41]^ have allowed clinicians to examine the impact of AKI on brain disease and identify a large vulnerable population at increased risk of stroke and all‐cause mortality.^[@b42]^

AKI Related to De Novo Stroke and Mortality
-------------------------------------------

Even after being adjusted for progression to subsequent CKD or ESRD, AKI still independently contributed to long‐term stroke events or all‐cause mortality. The patients who received temporary dialysis had higher severity of subsequent stroke in terms of ventilator use and critical care unit admission than the non‐AKI group. Furthermore, accumulating evidence suggests that the presence of underlying CKD modifies the outcomes of AKI but does not completely account for the impact of AKI.^[@b43]^ With detailed matching, we adjusted for traditional cardiovascular risks using uniform baseline comorbidities between the AKI‐recovery and non‐AKI groups. Consequently, the risk factors for kidney injury leading to an AKI event may persist^[@b44]^ and eventually lead to future stroke without a direct causal association with preexisting CKD. AKI may thus amplify the risk of long‐term incident stroke and mortality.

The effect of long‐term kidney--brain interactions was less clear. Our findings raise the possibility that AKI may trigger a cascade of perturbations that never completely resolve. The pathogenic mechanisms involved in this association may be related to nontraditional risk factors such as endothelial dysfunction, impaired endothelial progenitor cells, oxidative stress, inflammation, hyperhomocysteinemia, and thrombogenic factors during AKI.^[@b45]--[@b47]^ Each of these factors may play a role in accelerating atherosclerosis in the arteries of both the kidney and the brain, making AKI a nonmodifiable entity. The sudden decrease in systemic blood pressure during dialysis can cause a reduction in cerebral perfusion, leading to endothelial injury and subsequent stroke events. In addition, the dialysis hemofiltrate from patients with AKI has been shown to inhibit polymorphonuclear leukocyte chemotaxis, oxidative metabolism, and apoptosis in vitro, which could favorably influence the development of stroke.^[@b48]^ This indicates that AKI, in addition to traditional cardiovascular risk factors, is a "kidney specific" risk factor that has a causal relationship with future stroke. Increased serum concentrations of proinflammatory cytokines are putative mediators of remote organ effects during AKI and are believed to increase, in part, from subsequent impaired filtration and clearance of uremic toxins.^[@b49]^ An animal study demonstrated increased vascular permeability and an altered blood--brain barrier with inflammation including elevated levels of cytokines and granulocyte colony‐stimulating factor in mice undergoing renal ischemia.^[@b8]^ Furthermore, brain histology revealed increased microglial cells (brain macrophages) and pyknotic neuronal cells after AKI.^[@b8]^

Our results examining how much adjustment for interim CKD and ESRD attenuated the strength of the AKI--brain event association and how much adjustment for interim stroke attenuated the strength of the AKI--mortality association are important. Because AKI is gradually being recognized as a contributing factor to late‐stage CKD, it is possible that early kidney changes associated with endothelial phenotypic transition may have already taken place during acute events,^[@b50]^ leading to progressive deterioration. Recently, fibroblast growth factor‐23, a novel regulator of mineral metabolism, has been reported to be markedly elevated in AKI^[@b51]^ and to be an index of subclinical cardiovascular pathology in the community associated with adverse cardiovascular outcomes.^[@b52]--[@b53]^ Likewise, the expression of neutrophil gelatinase‐associated lipocalin, a marker of renal tubular injury, has also been associated with increased cardiovascular and all‐cause mortality independent of traditional cardiovascular risk factors.^[@b54]^

Disruption of the blood--brain barrier not only results in cerebral edema but also allows metabolites and toxins that are normally impermeable to the blood--brain barrier to cause changes to the central nervous system. Supporting this, numerous other reports have been published of encephalopathic events associated with AKI that are relevant to the known pathomechanisms of cerebral ischemia.^[@b55]--[@b56]^

DM and AKI Related to Stroke
----------------------------

The associated higher risk of stroke can only partly be explained by traditional risk factors such as DM, hypertension or dyslipidemia, and the kidney‐specific risks underlying AKI involved in the pathogenesis ([Figure 3](#fig03){ref-type="fig"}). This novel finding adds to the growing body of evidence suggesting that patients with AKI are at increased risk of stroke.

The kidney and brain share unique susceptibilities to vascular injury; therefore, some vascular risk factors may cause similar vascular injuries in both organs.^[@b57]--[@b58]^ No data on stroke have been reported with regard to the occurrence of AKI imposed on the course of DM, a factor known to have an impact on subsequent stroke.^[@b59]^ After a long‐term follow‐up period, we found that temporary dialysis had a similar effect to DM in causing de novo stroke independent of preexisting comorbidities.

The current study showed that the risk of developing stroke in the patients who had recovered from AKI was not statistically significantly associated with DM. In addition, the patients with AKI had a substantially higher mortality rate after stroke than the non‐AKI group, emphasizing the potential value of preventing stroke events in AKI patients. Recommendations regarding DM in the risk categorization for stroke could also be applied to patients who recover from AKI after dialysis. The US National Cholesterol Education Program Adult Treatment Panel III reported that 30% of cardiovascular disease events are accompanied by stroke and included DM as a risk equivalent to cardiovascular disease.^[@b60]--[@b61]^ Our results support the risk of stroke in patients with AKI, and the impact was similar to DM. Importantly, the patients with AKI had a higher mortality rate after a stroke event than those without AKI, further emphasizing the potential value of preventing stroke by targeting these conditions. In light of these findings, a comprehensive treatment strategy during admission or even after discharge for AKI patients is required to reduce the risk of ensuing stroke events and subsequent mortality. Taken together, AKI patients who undergo temporary dialysis are at a higher risk of subsequent stroke events compared with patients without AKI, supporting AKI as a cause of mortality.^[@b62]^

Study Limitations
-----------------

This study has several limitations. First, validation of stroke hospitalization was not possible from the data sources available for this study; however, the procedural and prescription codes used to identify stroke in our study have been shown to have high sensitivity and specificity for identifying true stroke hospitalizations in the general population.^[@b18]^ Second, the baseline glomerular filtration rate was not available from the ICD‐9‐CM codes; therefore, misclassification was possible. Third, approximately 4.15% of the patients who recovered from AKI were excluded because no matched controls could be identified. Because the excluded unmatched individuals had higher rates of stroke and mortality than the enrollees, their exclusion attenuated the reported effect sizes. Finally, cigarette smoking is likely to influence stroke; however, direct information on smoking was not available in the source data. Although we did not have any variables directly reflecting tobacco use, we believe that we controlled for the effect of tobacco use by including DM, myocardial infarction, lung cancer, and chronic obstructive pulmonary disease as proxy indicators for tobacco use (past and current use). AKI was significantly independent from these proxies for de novo stroke.

Conclusion
==========

The current study found that AKI requiring dialysis, even if only temporary dialysis, was associated with an increased risk of de novo stroke, and the impact was similar to DM. Our results suggest that a public health initiative is needed to monitor and control subsequent stroke among patients with dialysis‐requiring AKI, even among those whose kidney function has recovered after discharge, because dialysis‐requiring AKI may hasten subsequent long‐term stroke events and mortality.
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